Geron

Precision Medicine And Telomerase Inhibition Will Expand Therapeutic Markets

AnalystHighTarget

Not Invested

Consensus Narrative from 8 Analysts

Published

21 Aug 25

Updated

21 Aug 25

AnalystHighTarget's Fair Value

US$6.00

75.7% undervalued

21 Aug

US$1.46

-67.8%

0.7%

Author's Valuation

US$6.0

75.7% undervalued

AnalystHighTarget Fair Value

Narrative

Updates0

AnalystHighTarget Fair Value

US$6.0

75.7% undervalued

Future estimation in

% p.a.

Decrease

Increase

Current revenue growth rate

36.96%

Biotech revenue growth rate

11.97%

Risk Level (Discount Rate)

Our default considers factors like the company's size, volatility, profitablity and country of operation.

Decrease

Increase

Current discount rate

6.85%

Calculation

US$368.21m

Earnings '28

14.90x

PE Ratio '28

US$5.49b

Market Cap '28

US$5.49b

Market Cap '28

750.13m

No. shares '28

US$7.32

Share Price '28

US$7.32 Share Price '28

Discounted to 2025 @ 6.84% p.a.

US$6.00

Fair Value '25